# Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study

> **NCT05897372** · PHASE2 · TERMINATED · sponsor: **Iain Bressendorff** · enrollment: 1 (actual)

## Conditions studied

- Diabetic Kidney Disease

## Interventions

- **DRUG:** ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib

## Key facts

- **NCT ID:** NCT05897372
- **Lead sponsor:** Iain Bressendorff
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-01
- **Primary completion:** 2024-09-23
- **Final completion:** 2024-09-23
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05897372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05897372, "Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05897372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*